企業レポート

Valeant社の提携契約

Valeant Partnering Deals and Alliances 2010 to 2016

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 244588
出版日 ページ情報 英文 100+ pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
Valeant社の提携契約 Valeant Partnering Deals and Alliances 2010 to 2016
出版日: 2016年02月01日 ページ情報: 英文 100+ pages
概要

当レポートでは、Valeant社の企業動向および提携契約動向について調査分析し、詳細な企業プロファイル、提携契約活動の詳細(契約タイプ・開発フェーズ・治療領域別)、バイオ医薬品のトップ50社および大手医薬品事業者による取引動向、潜在的パートナーへのアプローチ法の検証などもまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 バイオ医薬品事業者トップ50社による各種取引

  • 提携
  • M&A

第3章 大手医薬品事業者による取引:取引額別

  • 大手医薬品事業者のM&A
  • 大手医薬品事業者による提携

第4章 潜在的パートナーへの提案

  • 提案の方法
  • 提案のテンプレート
  • Eメール送付
  • 提携イベントにおける面談
  • オンライン提案フォーム

第5章 今後の提携イベント

第6章 企業プロファイル

  • 企業プロファイルの利用方法
  • フィールドの定義
  • 提携契約ディレクトリー:産業セクター別
    • 大手医薬品
    • 医薬品
    • バイオテクノロジー
    • 診断
    • ドラッグデリバリー
    • 政府
    • 医療機器
    • 消費者医療
    • 特殊医薬品
    • ジェネリック医薬品
    • 農業
    • 動物医療
    • 学術部門
    • 非営利団体
    • 研究用ツール
    • サービス
  • 提携契約ディレクトリー:契約タイプ別
    • 資産購入
    • 共同開発
    • 共同販売
    • 共同プロモーション
    • 共同R&D
    • 委託サービス
    • 開発
    • 流通
    • 評価
    • ジョイントベンチャー
    • ライセンシング
    • 製造
    • マーケティング
    • プロモーション
    • 研究
    • ロイヤルティファイナンシング
    • 供給
  • 提携契約ディレクトリー:M&A
  • 提携契約ディレクトリー:開発ステージ別
    • 創薬
    • 前臨床
    • フェーズI
    • フェーズII
    • フェーズIII
    • 申請
    • 市販
    • 製剤
  • 提携契約ディレクトリー:治療区分別
    • 院内ケア
    • 心臓血管
    • 中枢神経系
    • 美容
    • 歯科
    • 皮膚科
    • 消化管
    • 遺伝性疾患
    • 尿生殖器
    • 血液
    • 免疫
    • 感染症
    • 炎症
    • 代謝性疾患
    • 筋骨格系
    • 眼科
    • 呼吸器系
    • 感覚器

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP1120

This report provides all the information you require to better understand Valeant and its partnering interests and activities since 2010.

The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.

On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.

The report will be delivered in PDF format within 1 working day of receipt of order. If the CD-Rom version purchased, the report will be sent by courier using express service.

One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives.

The initial chapters of this report provide an orientation of deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top companies partnering with the company since 2010. Chapter 3 provides an overview of the leading partnering and M&A deals since 2010 to present date based on headline value.

Chapter 4 provides details on how to approach biopharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where biopharma companies will be present to discuss opportunities face to face.

The main body of the report is provided in chapter 6 providing a infographic visual summary of the company's partnering activity since 2010 according to deal type, industry sector, phase of development, and therapy area.

The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of prospective partners' negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

In addition, contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Each contract document is accessible through a link to an online version of the actual contract document as filed with the Securities Exchange Commission. Analyzing actual company agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and sub-contracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Partnering Deals and Alliances since 2010 report provides the user with the following key benefits:

  • Partnering interests and therapy focus revealed
  • Partnering activity since 2010 - number of deals per year
  • Partnering activity for 2010-present
  • Activity by deal type
  • Activity by phase of development
  • Activity by therapeutic area
  • List of recent partner companies
  • Detailed listing of all partnering deals since 2010
  • Comprehensive access to actual contracts entered into by the company and its partners*
  • Insight into the terms included in a partnering agreement
  • Understand the key deal terms the company has agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
  • Subject to being published via regulatory requirements of the Securities Exchange Commission.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Most active partner companies

  • 2.1 Most frequent partner companies

Chapter 3 - Top deals by value

  • 3.1 M&A
  • 3.2 Partnering

Chapter 4 - Submitting Opportunities

  • 4.1 How to submit an opportunity
  • 4.2 Opportunity submission template
  • 4.3 Sending emails
  • 4.4 Face to face at partnering events
  • 4.5 Online submission forms

Chapter 5 - Forthcoming partnering events

  • 5.1 Forthcoming events

Chapter 6 - Partnering and M&A directory since 2010

  • 6.1 How to use directory
  • 6.3 Company directory
  • Infographic summary for partnering activity since 2010
  • Partnering deals directory - by company A-Z
  • Partnering deals directory - by industry sector
  • Partnering deals directory - by deal type
  • Partnering deals directory - M&A
  • Partnering deals directory - by stage of development
  • Partnering deals directory - by therapy area
  • Partnering deals directory - by technology area
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent titles from CurrentPartnering

TABLE OF FIGURES

  • Figure 1: Most frequent partner companies since 2010
  • Figure 2: Leading M&A deals by value since 2010
  • Figure 3: Leading partnering deals by value since 2010
  • Figure 4: Typical partnering opportunity submission template
  • Figure 5: Dealmaking frequency since 2010
  • Figure 6: Recent deals by industry sector
  • Figure 7: Recent deals by deal type
  • Figure 8: Recent deals by stage of development
  • Figure 9: Recent deals by therapy area
  • Figure 10: Recent deals by technology area
Back to Top